Machine log file-based dose verification using novel iterative CBCT reconstruction algorithm in commercial software during volumetric modulated arc therapy for prostate cancer patients - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34837857/
doi: 10.1016/j.ejmp.2021.11.004. Online ahead of print. 1 Department of Radiation Oncology, Osaka International Cancer Institute, Osaka, Japan; Department of Medical Physics and Engineering, Osaka University Graduate School of Medicine, Suita,...
Conclusion/Relevance: A similar machine log file-based dose verification accuracy is obtained for FDK-CBCT and iCBCT during VMAT for prostate cancer patients.
A prostate cancer tissue specific spectral library for targeted proteomic analysis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34799972/
doi: 10.1002/pmic.202100147. Online ahead of print. 1 Zhejiang University, Hangzhou, China. 2 Key Laboratory of Structural Biology of Zhejiang Province, School of Life Sciences, Westlake University, Hangzhou, 310024, China. 3...
Conclusion: Here we provide a comprehensive tissue-specific spectral library for targeted proteomic analysis of prostate tissue samples. Benign and malignant FFPE prostate tissue samples were processed into peptide samples by pressure cycling technology (PCT)-assisted sample preparation, and fractionated with high-pH reversed phase...
Targeted fluorescent imaging of a novel FITC-labeled PSMA ligand in prostate cancer - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34800176/
doi: 10.1007/s00726-021-03102-8. Online ahead of print. 1 Chinese PLA General Hospital, Chinese PLA Medical School, Beijing, 100853, China. 2 Department of Nuclear Medicine, Chinese PLA General Hospital, Beijing, 100853, China....
Conclusion:A novel FITC-labeled PSMA ligand (PSMA-FITC) was synthesized by Fmoc solid-phase synthesis. PSMA-FITC has high sensitivity and specificity for PSMA( ) prostate cancer. The rapid targeting and high tumor-background contrast of PSMA-FITC proved that PSMA ligand-mediated prostate cancer-targeted fluorescence imaging has high potential...
-
Prostate Cancer Connect4yr• Source: Amino Acids • Conclusion/Relevance: “PSMA-FITC is a promising probe and has important reference value for the development of PSMA fluorescent probes. In the future, it can be applied to obtain accurate Show More
Novel combination therapy of prostate cancer cells with arsenic trioxide and flutamide: An in-vitro study - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34800879/
doi: 10.1016/j.tice.2021.101684. Online ahead of print. 1 Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran. 2 Women's College Research Institute, Women's College Hospital, University of Toronto, Canada; Institute...
Conclusion: The combination therapy with ATO and flutamide has augmented the anti-tumor effect on LNCaP and PC3 cells, which probably originates from their potential to induce apoptosis and inhibit the proliferation of PCa cells simultaneously.
68 Ga-PSMA PET/CT for response assessment and outcome prediction in metastatic prostate cancer patients treated with taxane-based chemotherapy - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34772793/
Aim: We aimed to evaluate the role of Positron Emission Tomography (PET) targeting the Prostate-Specific Membrane Antigen (PSMA) for response assessment in metastatic prostate cancer (mPCa) patients treated with taxane-based...
This retrospective analysis suggests that 68Ga-PSMA-11 PET/CT is a promising imaging modality for assessing response to taxane-based chemotherapy in mPCa. PSMA-expression changes might be used as a predictive biomarker for OS which might help tailor individual therapy and select eligible patients for clinical trials.